Wontech, a leading provider of laser and energy-based medical solutions, announced on Thursday that its advanced combination laser device, the SANDRO Dual 2026 model, has received certification from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and Taiwan’s Food and Drug Administration (TFDA).
This latest approval follows the device’s U.S. Food and Drug Administration (FDA) certification in December, signaling Wontech’s accelerated push into the global laser hair removal market.
Regulatory bodies in Japan and Taiwan have green-lit the SANDRO Dual 2026 for dermatological procedures, including hair removal, pigmentation treatment, and vascular therapy.
The SANDRO Dual’s innovative design incorporates dual wavelengths of 755 nm and 1064 nm, featuring a unique hybrid mode that delivers these wavelengths in rapid succession. This technology enables precise energy targeting with minimal power requirements.
Additionally, the device’s integrated cooling system significantly reduces common side effects such as pain, swelling, and redness during treatments.
As the demand for non-invasive cosmetic procedures continues to surge, there’s growing interest in laser technologies capable of addressing diverse skin types with precision. The SANDRO Dual’s versatility, particularly its hybrid mode, has captured industry attention for its ability to effectively treat a wide range of skin types.
Market research firm Grand View Research projects that the global laser hair removal market will expand from 1.1 billion USD in 2023 to approximately 3.6 billion USD by 2030, boasting an impressive annual growth rate of 18.8%.
The Asia-Pacific region is expected to lead this growth, with Chinese and Japanese markets showing particularly strong potential.
A Wontech spokesperson commented that securing output enhancement certifications from Japan’s PMDA and Taiwan’s TFDA, following the U.S. FDA approval, underscores the international recognition of the SANDRO Dual 2026’s cutting-edge technology. It is poised to leverage these approvals to build the clinical reference base and strengthen the partner networks in Japan and Taiwan, using these markets as springboards for broader Asian expansion.
The spokesperson added that the strategy involves systematically obtaining certifications in key global markets to aggressively increase the worldwide market share.
Wontech currently derives over 70% of its revenue from international sales. The company has secured major global certifications, including those from the U.S. FDA, Australia’s Therapeutic Goods Administration (TGA), Europe’s Conformité Européenne (CE), and Thailand’s FDA, enabling product exports to more than 80 countries.
Looking ahead, Wontech aims to further expand its global footprint, with a focus on its subsidiaries in the U.S., Japan, and Thailand, as part of its strategy to boost its international revenue share.
